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background:  Transcatheter aortic valve replacement (TAVR) leads to substantial reductions in mortality and morbidity in patients with 
severe aortic stenosis at high perioperative risk. Up to 50 percent of these individuals still die or have to be rehospitalized during the 
first year after the procedure. This emphasizes the need for more strategic patient selection. The aim of our study was to compare the 
prognostic performance of 4 risk scores (logistic EuroSCORE, EuroSCORE II, STS-PROM, German Aortic Valve score) and 5 circulating 
biomarkers of inflammation and/or myocardial dysfunction (hsCRP, GDF-15, IL-6, IL-8, NTproBNP), alone and in combination, to predict 
all-cause mortality and major adverse cardiac events (MACE, all-cause mortality or rehospitalization) in the first year after TAVR.
methods:  We calculated the hazard ratios and c-statistics (AUC) of risk scores and biomarkers for 1-year all-cause mortality (N=80) or 
MACE (N=132) in 310 consecutive TAVR patients. The magnitude of the increase in model performance when combining risk scores 
and biomarkers was evaluated by the change in the c-statistic (ΔAUC), integrated discrimination improvement (IDI), and continuous net 
reclassification improvement [NRI(>0)].
results:  The EuroSCORE II and GDF-15 had the strongest predictive value for 1-year mortality (EuroSCORE II, AUC 0.711; GDF-15, 
AUC 0.686) and MACE (EuroSCORE II, 0.690; GDF-15, 0.682). When added to the EuroSCORE II, GDF-15, and to a lesser extent IL-8, 
enhanced the prognostic performance of the score and enabled substantial reclassification of patients. Combinations of increasing tertiles 
of the EuroSCORE II and GDF15 identified patient subgroups with mortality rates ranging from 8.5 to 49.1% and MACE rates ranging from 
15.3 to 68.4%. NT-proBNP did not add prognostic information to the EuroSCORE II.
Conclusion:  Our study identified the EuroSCORE II and GDF-15, alone and in combination, as the most promising predictors of a poor 
outcome after TAVR. Risk score/biomarker combinations may support the decision making process in patients considered for TAVR.
